Cargando…
Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications
SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956655/ https://www.ncbi.nlm.nih.gov/pubmed/33669017 http://dx.doi.org/10.3390/cancers13050963 |
_version_ | 1783664486084771840 |
---|---|
author | Bella, Ángela Di Trani, Claudia Augusta Fernández-Sendin, Myriam Arrizabalaga, Leire Cirella, Assunta Teijeira, Álvaro Medina-Echeverz, José Melero, Ignacio Berraondo, Pedro Aranda, Fernando |
author_facet | Bella, Ángela Di Trani, Claudia Augusta Fernández-Sendin, Myriam Arrizabalaga, Leire Cirella, Assunta Teijeira, Álvaro Medina-Echeverz, José Melero, Ignacio Berraondo, Pedro Aranda, Fernando |
author_sort | Bella, Ángela |
collection | PubMed |
description | SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedical research. ABSTRACT: Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents. |
format | Online Article Text |
id | pubmed-7956655 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79566552021-03-16 Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications Bella, Ángela Di Trani, Claudia Augusta Fernández-Sendin, Myriam Arrizabalaga, Leire Cirella, Assunta Teijeira, Álvaro Medina-Echeverz, José Melero, Ignacio Berraondo, Pedro Aranda, Fernando Cancers (Basel) Review SIMPLE SUMMARY: Peritoneal carcinomatosis mouse models as a platform to test, improve and/or predict the appropriate therapeutic interventions in patients are crucial to providing medical advances. Here, we overview reported mouse models to explore peritoneal carcinomatosis in translational biomedical research. ABSTRACT: Peritoneal carcinomatosis of primary tumors originating in gastrointestinal (e.g., colorectal cancer, gastric cancer) or gynecologic (e.g., ovarian cancer) malignancies is a widespread type of tumor dissemination in the peritoneal cavity for which few therapeutic options are available. Therefore, reliable preclinical models are crucial for research and development of efficacious treatments for this condition. To date, a number of animal models have attempted to reproduce as accurately as possible the complexity of the tumor microenvironment of human peritoneal carcinomatosis. These include: Syngeneic tumor cell lines, human xenografts, patient-derived xenografts, genetically induced tumors, and 3D scaffold biomimetics. Each experimental model has its own strengths and limitations, all of which can influence the subsequent translational results concerning anticancer and immunomodulatory drugs under exploration. This review highlights the current status of peritoneal carcinomatosis mouse models for preclinical development of anticancer drugs or immunotherapeutic agents. MDPI 2021-02-25 /pmc/articles/PMC7956655/ /pubmed/33669017 http://dx.doi.org/10.3390/cancers13050963 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Bella, Ángela Di Trani, Claudia Augusta Fernández-Sendin, Myriam Arrizabalaga, Leire Cirella, Assunta Teijeira, Álvaro Medina-Echeverz, José Melero, Ignacio Berraondo, Pedro Aranda, Fernando Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title | Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title_full | Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title_fullStr | Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title_full_unstemmed | Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title_short | Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications |
title_sort | mouse models of peritoneal carcinomatosis to develop clinical applications |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956655/ https://www.ncbi.nlm.nih.gov/pubmed/33669017 http://dx.doi.org/10.3390/cancers13050963 |
work_keys_str_mv | AT bellaangela mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT ditraniclaudiaaugusta mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT fernandezsendinmyriam mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT arrizabalagaleire mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT cirellaassunta mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT teijeiraalvaro mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT medinaecheverzjose mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT meleroignacio mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT berraondopedro mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications AT arandafernando mousemodelsofperitonealcarcinomatosistodevelopclinicalapplications |